Date: 2011-06-23
Type of information: Distribution agreement
Compound: Xerclear® (Xerese® in the USA) combination of 5% acyclovir and 1% hydrocortisone in Medivir’s proprietary cream formulation
Company: Medivir (Sweden) Daewoong Pharmaceutical (South Korea)
Therapeutic area: Infectious diseases
Type agreement: distribution
Action mechanism:
Disease: recurrent herpes labialis
Details: Medivir has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir’s unique cold sore treatment Xerclear® in China and Hong Kong. Under the terms of the agreement, Daewoong will be responsible for conducting clinical studies for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir’s cold sore product in the territory. In return, Medivir will receive royalties on all product sales. Daewoong is also responsible for the commercialisation of Xerclear® in South Korea. Daewoong has recently filed for registration with the South Korean authorities and expects the regulatory approval later this year.
Financial terms:
Latest news:
